Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
1990 78
1991 187
1992 257
1993 302
1994 265
1995 288
1996 206
1997 202
1998 136
1999 113
2000 124
2001 142
2002 201
2003 202
2004 231
2005 171
2006 190
2007 244
2008 215
2009 186
2010 234
2011 236
2012 270
2013 281
2014 457
2015 515
2016 645
2017 617
2018 573
2019 584
2020 705
2021 796
2022 725
2023 679
2024 670
2025 653
2026 367

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

11,547 results

Results by year

Filters applied: . Clear all
Page 1
Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy.
Desai MY, Owens AT, Abraham T, Olivotto I, Garcia-Pavia P, Lopes RD, Elliott P, Fernandes F, Verheyen N, Maier L, Meder B, Azevedo O, Kitaoka H, Wolski K, Wang Q, Jaber W, Mitchell L, Myers J, Rano T, Gong Z, Zhong Y, Carter-Bonanza S, Florea V, Aronson R, Nissen SE; ODYSSEY-HCM Investigators. Desai MY, et al. N Engl J Med. 2025 Sep 11;393(10):961-972. doi: 10.1056/NEJMoa2505927. Epub 2025 Aug 30. N Engl J Med. 2025. PMID: 40888717 Clinical Trial.
Adagrasib versus docetaxel in KRASG12C-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trial.
Barlesi F, Yao W, Duruisseaux M, Doucet L, Martínez AA, Gregorc V, Juan-Vidal O, Lu S, De Bondt C, de Marinis F, Linardou H, Kim YC, Jotte R, Felip E, Lo Russo G, Reck M, Michenzie MF, Yang W, Meade JN, Korytowsky B, Mok TSK; KRYSTAL-12 Investigators. Barlesi F, et al. Lancet. 2025 Aug 9;406(10503):615-626. doi: 10.1016/S0140-6736(25)00866-9. Lancet. 2025. PMID: 40783289 Clinical Trial.
Cendakimab in Adults and Adolescents with Eosinophilic Esophagitis.
Dellon ES, Charriez CM, Zhang S, Falk GW, Oliva S, Ma C, Siffledeen J, Schroeder S, Philpott H, Vanuytsel T, Abe Y, Li K, Zema CL, Venkatasamy A, Yeshokumar AK, Oh YS, Schoepfer A. Dellon ES, et al. NEJM Evid. 2025 Oct;4(10):EVIDoa2500095. doi: 10.1056/EVIDoa2500095. Epub 2025 Sep 23. NEJM Evid. 2025. PMID: 40985784 Clinical Trial.
Pathophysiology and Therapeutic Needs in Nonobstructive Hypertrophic Cardiomyopathy.
Desai MY, Maurizi N, Biagini E, Charron P, Fernandes F, González-López E, van Haelst PL, Haugaa KH, Kramer CM, Meder B, Michels M, Owens A, Yuasa S, Elliott P. Desai MY, et al. JACC Heart Fail. 2025 Nov;13(11):102658. doi: 10.1016/j.jchf.2025.102658. Epub 2025 Sep 24. JACC Heart Fail. 2025. PMID: 40997544 Free article. Review.
Final analysis of nivolumab plus cabozantinib for advanced renal cell carcinoma from the randomized phase III CheckMate 9ER trial.
Motzer RJ, Escudier B, Burotto M, Powles T, Apolo AB, Bourlon MT, Shah AY, Porta C, Suárez C, Barrios CH, Richardet M, Gurney H, Kessler ER, Tomita Y, Bedke J, Scheffold C, Askelson M, Panzica J, Zhang J, van Kooten Losio M, Choueiri TK. Motzer RJ, et al. Ann Oncol. 2026 Jan;37(1):33-43. doi: 10.1016/j.annonc.2025.09.006. Epub 2025 Sep 23. Ann Oncol. 2026. PMID: 40998092 Free article. Clinical Trial.
Combination of the MTA-Cooperative PRMT5 Inhibitor BMS-986504 and KRAS Inhibitors Is an Effective Treatment Strategy for MTAP-Deleted KRAS-Mutant Pancreatic Cancer.
Drizyte-Miller K, Engstrom LD, Klomp JA, Stalnecker CA, Stamey AG, Taylor KE, Roach MK, Robb R, Waters LM, Calinisan A, Degan S, Chang WH, Helu XM, Nguyen D, Baldelli E, Pierobon M, Petricoin EF, Briere DM, Hallin J, Christensen JG, Bryant KL, Cox AD, Olson P, Der CJ. Drizyte-Miller K, et al. Cancer Res. 2025 Sep 15;85(18):3540-3557. doi: 10.1158/0008-5472.CAN-25-1507. Cancer Res. 2025. PMID: 40694535 Free PMC article.
A Tumor-Promoting Inflammatory SPP1+ Macrophage-IL6-CRP Axis Drives Immune Dysfunction in Bladder Cancer.
Tran MA, Cho BA, Izadmehr S, Yoo SK, Youssef D, Anker JF, Farkas AM, Figueiredo I, Lee K, Ananthanarayanan A, Balan S, Onkar S, Banchereau R, Gupta S, Chhibber A, Wang L, Beaumont KG, Li Z, Garcia-Barros M, Bicak M, Cordon-Cardo C, Brody R, Kim-Schulze S, Yuen K, Mariathasan S, Atiq SO, Adeyelu TT, Elliott A, Barata P, McKay RR, Gnjatic S, Gonzalez-Kozlova E, Mehrazin R, Horowitz A, Sfakianos JP, Chowell D, Galsky MD, Bhardwaj N. Tran MA, et al. Cancer Discov. 2026 Jun 1;16(6):1126-1151. doi: 10.1158/2159-8290.CD-25-1774. Cancer Discov. 2026. PMID: 41747249 Free PMC article.
Adjuvant nivolumab versus placebo for high-risk muscle-invasive urothelial carcinoma: 5-year efficacy and ctDNA results from CheckMate 274.
Galsky MD, Gschwend JE, Milowsky MI, Schenker M, Valderrama BP, Tomita Y, Bamias A, Lebret T, Shariat SF, Park SH, Agerbaek M, Jha G, Stenner F, Ye D, Giudici F, Connors J, Gupta S, Chhibber A, Zhang J, Bajorin DF, Witjes JA. Galsky MD, et al. Ann Oncol. 2026 Jan;37(1):69-78. doi: 10.1016/j.annonc.2025.09.139. Epub 2025 Oct 17. Ann Oncol. 2026. PMID: 41110694 Free article. Clinical Trial.
Nivolumab for Resected Stage III or IV Melanoma at 9 Years.
Ascierto PA, Del Vecchio M, Merelli B, Gogas H, Arance AM, Dalle S, Cowey CL, Schenker M, Gaudy-Marqueste C, Pigozzo J, Márquez-Rodas I, Butler MO, Di Giacomo AM, Gligich O, De La Cruz-Merino L, Arenberger P, Atkinson V, Nathan P, Hill A, Millward M, Fecher LA, Khushalani NI, Queirolo P, Soomro R, Rathod D, Askelson M, Pe Benito M, Joseph D, Larkin J. Ascierto PA, et al. N Engl J Med. 2026 Jan 22;394(4):333-342. doi: 10.1056/NEJMoa2504966. Epub 2025 Oct 18. N Engl J Med. 2026. PMID: 41124198 Clinical Trial.
11,547 results
You have reached the last available page of results. Please see the User Guide for more information.